Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 890886 10.3389/fphar.2022.890886 Pharmacology Correction Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance Lin et al. Corrigendum: A Systematic Pre-Clinic Study of Diplatin Lin Xixi 1 † ‡ Jia Yongliang 2 3 ‡ Dong Xinwei 2 3 Shen Jian 2 3 Jin Yachao 3 Li Yanyou 4 Wang Fang 5 Anenberg Eitan 1 Zhou Jiancang 6 Zhu Jianping 6 Chen Xiaoping 4 Xie Qiangmin 1 2 Xie Yicheng 1 * 1 Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China 2 Zhejiang Respiratory Drugs Research Laboratory of Food and Drug Administration of China, Zhejiang University School of Medicine, Hangzhou, China 3 Breath Smooth Biotech Hangzhou Co., LTD, Hangzhou, China 4 Beijing Shuobai Pharmaceutical Co., LTD, Beijing, China 5 Joinn Laboratories, BAD, Beijing, China 6 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

Edited and reviewed by: Fabrizio Marcucci, University of Milan, Italy

 *Correspondence: Yicheng Xie, ycxie@zju.edu.cn

Present Address: Xixi Lin, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China

These authors have contributed equally to this work

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

 28 04 2022 2022 13 890886 07 03 2022 05 04 2022 Copyright © 2022 Lin, Jia, Dong, Shen, Jin, Li, Wang, Anenberg, Zhou, Zhu, Chen, Xie and Xie. 2022 Lin, Jia, Dong, Shen, Jin, Li, Wang, Anenberg, Zhou, Zhu, Chen, Xie and Xie

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance by Lin, X., Jia, Y., Dong, X., Shen, J., Jin, Y., Li, Y., Wang, F., Anenberg, E., Zhou, J., Zhu, J., Chen, X., Xie, Q., Xie, Y. (2019). Front. Pharmacol. 10:982. doi: 10.3389/fphar.2019.00982 lung cancer Platinum complex Water solubility ROS/p53 pathway cisplatin resistance

In the original article, there was a mistake in Figure 3H as published. An incorrect image for the p53 measurement in A549 was shown. The corrected Figure 3H appears below.

JNK/p53-mediated pathway is involved in diplatin-induced apoptosis of tumor cells. (H) Pretreatment (0.5 h) with 10 μM JNK inhibitor (SP600125) suppresses the 48 h time point 25 μM diplatin-induced p53, Fas, and Bax protein upregulation (n = 4 per group). The data are presented as mean ± SEM from three independent experiments, one-way ANOVA followed by the Student-Newman-Keuls test. Statistical significance is indicated by *p < 0.05, **p < 0.01, and ***p < 0.001 for comparison with control and #p < 0.05, ##p < 0.01 for comparison with the diplatin-treated group.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.